atai Life Sciences · pitchdeck
ATAI | Investor Presentation Deck | 36 slides
36 pages · 0 arc beats · 0 loops
ATAI | Investor Presentation Deck | 36 slides
atai Life Sciences · 2022-11 arc beats above · slides in the middle · loops below · scroll → 0 LOOPS
124681012141618202224262830323436
Deck intelligence map
1 coverage by narrative range · generated from this deck JSON
Narrative range 36 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Whole deck 36 slides 100% 36/36 slides 100% 36/36 slides · 187 hits — 0/36 slides
16.7% 6/36 slides · 7 hits 50% 18/36 slides — 0/36 slides
— 0/36 slides
Slide inventory
36 every slide · same image gating as the playbook
03
The slide uses a numbered list to present five key pillars of the company's current status.summarize
04
The slide uses a combination of headshots for the team and a metric-based footer to establish credibility.other
05
The slide uses a hierarchical structure to connect a high-level objective to three distinct operational pillars.present_solution
06
The slide uses a Gantt-style visualization to represent the clinical development status of multiple drug candidates.plan_implementation
07
The slide uses a hub-and-spoke diagram to represent the platform model.present_solution
08
The slide uses a timeline framework to contrast past achievements with future clinical trial milestones.plan_implementation
10
The slide uses a minimalist design with a portrait of a person to evoke an emotional connection to the topic.transition
11
The slide uses a split-layout: left side defines the condition and market size, right side details the clinical and regulatory pain points.frame_problem
12
Includes clinical trial data visualization and product summary table.show_traction
13
The slide uses a side-bar summary format alongside a clinical trial chart.summarize
14
The slide uses a split-layout with a dark sidebar for key facts and a white main area for clinical data visualization.summarize
15
Includes chemical structure diagrams and multiple bar charts showing dose-response relationships.compare_peers
16
The chart uses a dot plot to show individual patient CADSS scores over time across three cohorts (30mg, 60mg, Placebo).show_traction
17
The slide uses a timeline diagram to illustrate the clinical trial flow and two boxes to detail study design and operational status.plan_implementation
18
The slide uses a checkmark system to highlight competitive advantages in 'at home use', 'sustained efficacy', and 'rapid onset'.compare_peers
20
The slide uses a split-layout: left side defines the condition and global burden, right side details the 'huge need for development' using a vertical timeline-lframe_problem
21
The slide uses a vertical process flow to map clinical development stages to specific de-risking outcomes.show_traction
22
Includes a quote from Keith Nuechterlein and a detailed clinical trial timeline.summarize
23
The slide highlights efficacy in cognitive endpoints for a specific patient population (DPNP).show_traction
24
CIAS likely refers to Cognitive Impairment Associated with Schizophrenia.show_traction
27
The slide uses a split-layout: left side provides market context and statistics, right side outlines the 'unaddressed need' framework.size_opportunity
29
The slide uses a checkmark matrix to highlight the competitive advantage of the company's drug candidate.compare_peers
31
Uses a combination of a map, metric callouts, and a vertical process-style list to convey urgency.size_opportunity
32
Includes a summary table on the left and clinical trial data/roadmap on the right.summarize
33
The table highlights the unique value proposition of DMX-1002 (DemeRx) compared to traditional withdrawal support and medication-assisted therapies.compare_peers
35
Page number 35. The slide uses a card-based layout to describe portfolio companies.other